News and Announcements
Browse the articles below to learn more about our faculty’s latest achievements, awards and honors.
Men with high-risk prostate cancer who received immunotherapy treatment with enoblituzumab in the weeks leading up to surgery had favorable rates of disease remission and tumor downgrading after surgery, according to a recent study published in Nature Medicine.
- New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients05.03.2023A new biomarker based on gene expression has been discovered that can classify prostate cancer into distinct molecular subtypes. This classification system could aid doctors in creating personalized treatment plans for patients with prostate cancer. The biomarker utilizes Veracyte's Decipher Genomics Resource for Intelligent Discovery database. The study, senior authored by Edward M. Schaeffer, MD, PhD, was published in the journal Cancer .
- 05.01.2023During the 2023 American Urological Association Residents' Forum, an esteemed panel of urology leaders in international surgery shared their experiences on how they've successfully integrated this global pursuit into their respective careers. Notable panelists included Stephanie Kielb, MD.
- AUA 2023: Characteristics and Outcomes of Patients with Advanced Prostate Cancer Treated with Relugolix: A Single Center Experience05.01.2023During the 2023 American Urological Association Annual Meeting in Chicago, Parth Shah from Dr. Ashley Ross`s lab, delivered a presentation on relugolix treatment outcomes for advanced prostate cancer. This included an analysis of patient characteristics and their corresponding outcomes, conducted at a single center.
- 05.01.2023The 2023 Annual American Urological Association Conference held in Chicago, Illinois hosted a significant debate regarding the renaming of Gleason 6 Prostate Cancer. Dr. William Catalona voiced his opposition to the proposed change, which sparked discussions on the accuracy of the current Gleason scoring system and the potential benefits of renaming the cancer.
- 05.01.2023Northwestern Medicine researchers have created a biomarker signature test to identify which bladder cancer tumors will respond to immunotherapy. This discovery, led by Joshua Meeks, MD, PhD, is expected to enhance the survival rates of patients suffering from this disease.
- 04.30.2023Dr. Amy E. Krambeck shares important insights from the BPH Update, presented at the 2023 American Urological Association Annual Meeting in Chicago. This video delivers key takeaways aimed at increasing awareness and understanding of benign prostatic hyperplasia (BPH).
- 04.28.2023Nick Dean presented a study at the 2023 American Urological Association Annual Meeting, revealing that HoLEP's functional outcomes were comparable in patients, regardless of prior BPH procedures. This indicates that HoLEP remains effective in improving urinary symptoms and preserving bladder function, irrespective of a patient's BPH treatment history.
- 04.28.2023Eric Li, MD, a urology resident presented findings from his study titled “Prostate Health Index is associated with Incidental Prostate Cancer Detection at Time of Holmium Laser Enucleation of the Prostate” at the 2023 Annual American Urological Association Conference in Chicago, Illinois. The study sheds light on the connection between Prostate Health Index and incidental prostate cancer detection during Holmium Laser Enucleation of the Prostate.
- Urologists Explore Laws Affecting Male Infertility Treatment and the First Nonhormonal Hydrogel-Based Male Contraceptive04.28.2023The American Urological Association's 118th Annual Scientific Meeting will feature noteworthy research on male infertility treatment laws and the pioneering nonhormonal hydrogel-based male contraceptive. These findings will be presented by urologists seeking to advance fertility studies.
- 04.27.2023Northwestern Medicine researchers have developed a biomarker signature test that can predict which bladder cancer tumors will positively respond to immunotherapy, potentially improving survival rates for patients. This breakthrough discovery provides clinicians with a valuable tool to enhance treatment options and fight against bladder cancer.
- 04.21.2023Drs. Eric Li and Rashid Siddiqui, Urology residents from Dr. Ashley Ross`s lab, discussed the groundbreaking article "Optimizing detection of clinically significant prostate cancer through nomograms incorporating MRI, clinical features, and advanced serum biomarkers in biopsy naive men" published in Prostate Cancer and Prostatic Diseases. They are currently investigating ways to implement the study's findings and spearhead this innovative approach.
- 04.20.2023Dr. Alan W. Partin passed away at the age of 62 on March 28, 2023. He made significant contributions to the field of urology throughout his career and served as the director of the Brady Urological Institute and urologist-in-chief at Johns Hopkins Medicine in Baltimore, Maryland. Edward M. Schaeffer, MD, PhD, paid tribute to Dr. Partin for his remarkable achievements and dedication to advancing the field.
- 04.18.2023According to recent research conducted by Cedars-Sinai Cancer, African American men with a deficiency in vitamin D may face a higher risk of developing prostate cancer at a younger age, which is more aggressive in nature. The study involved the contribution of Adam Murphy, MD.
- 03.13.2023Adam Murphy, MD, MBA, MSCI, discusses potential legislative directions for PSA screening recommendations moving forward from the 2023 AUA Summit, where he was part of the discussion "Breaking Down Barriers to PSA Screening.
- 03.08.2023Ricardo M. de Oliveira Soares, MD, explains the development of incontinence in patients who have undergone prostatectomy.
- 02.27.2023Joshua J. Meeks, MD, PhD, provides insights into a promising pilot study on the treatment of advanced urothelial carcinoma using tazemetostat and pembrolizumab.
- Direct-to-Consumer Online Platforms Expand Access, but Often Fail to Convey Risks of Testosterone Therapy01.05.2023
Direct-to-consumer platforms for testosterone therapy don’t always provide care in concordance with professional guidelines, according to a recent Northwestern Medicine study.
- Direct-to-Consumer Online Platforms Expand Access, but Often Fail to Convey Risks of Testosterone Therapy12.05.2022Northwestern Medicine “Secret Shopper” study is the first to identify guideline-discordant practices among online men’s health providers
- 12.05.2022While demand for testosterone therapy has soared in the United States, a new study co-authored by Joshua Halpern, MD, MS, found that several direct-to-consumer companies offering the therapy did not follow medical guidelines nor convey the health risks of therapy.
- From Science to Clinical Utility: Cxbladder Detect - Bladder Cancer Detection for Patients Who Present with Hematuria - Tamer Aboushwareb, Neal Shore & Josh Meeks11.21.2022
Dr. Joshua Meeks joines a discussion with Drs. Neal Shore and Tamer Aboushwareb to provides an overview of the Cxbladder Detect urine-based cancer diagnostic test and discuss the clinical implications of the use of this test which is designed for high-risk patients who present with hematuria.
- 11.18.2022Urology Times is celebrating its 50th anniversary in 2022. To mark the occasion, they highlighted 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. Ziho Lee, MD, discusses the buccal mucosa graft for urethral and ureteral stricture disease.
- 11.14.2022Meeks recaps a panel discussion on ABCC optimization, which took place at the 2022 LUGPA Annual Meeting in Chicago
Joshua J. Meeks, MD, discusses investigational targets in the bladder cancer space.
- 11.11.2022In an interview during the 2022 LUGPA Annual Meeting, Diana K. Bowen, MD, discusses ways to make gender-diverse patients feel welcome in practices.
In an interview during the 2022 LUGPA Annual Meeting, Ashley Ross, MD, PhD, discussed these advances as well as unmet needs in prostate cancer.
During the 2022 LUGPA Annual Meeting, Ashley Ross, MD, PhD, associate professor of Urology and the clinical director of the Polsky Urologic Cancer Institute at Northwestern University, discusses the emergence of PSMA-PET in prostate cancer.
Expert panelists including Ashley Ross, MD, PhD, review risk stratification strategies for patients with prostate cancer and summarize the evolving use of conventional versus newer imaging modalities for diagnosis, treatment selection, and monitoring of these patients.